Bortezomib Recruiting Phase 2 Trials for Mantle Cell Lymphoma (MCL) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03617484Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
NCT02840539Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma